Please Wait
Applying Filters...
menu
    • menu
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone;methanesulfonic acid

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,073Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    30/12/2024 Fareva
    Luxembourg
    		 Samoh Pharmaceutical Co., Ltd. 20050831-14-B-58-02 Mesilsan Doxazosin 2005-08-31 Excella GmbH & Co. KG Germany Nurnberger Str. 12 90537 Feucht, Germany (Sudwestpark 50 90449 Nurnberg, Germany)
    30/12/2024 Fareva
    Luxembourg
    		 Hanmi Pharmaceutical Co., Ltd. 20050831-14-B-58-02(1) Mesilsan Doxazosin 2019-01-11 Excella GmbH & Co. KG Germany Nurnberger Str. 12 90537 Feucht, Germany (Sudwestpark 50 90449 Nurnberg, Germany)